Efficacy of a low-dose leuprolide acetate depot in the treatment of uterine leiomyomata in Japanese women.

Watanabe Y, Nakamura G, Matsuguchi H, Nozaki M, Sano M, Nakano H

Fertility and sterility1 Jul 1992Cited by 30 (Europe PMC)

PMID1624025DOI10.1016/s0015-0282(16)55138-3PepBankPUB-01624025

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In Japanese women with leiomyomata, uterine volume reduction did not differ significantly between leuprolide doses at each treatment week.
In plain wordsIn Japanese women with fibroids, uterine volume reduction did not differ significantly between leuprolide doses.
Peptide
Leuprolide
Outcome
No significant changeUterine volume reduction
Study
n = 41
Comparator
Leuprolide 3.75 mg every 4 weeks
Outcome group
Uterine volume · Reproductive and sexual health
Studied dose
1.88 mg every 4 weeks · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
No significant difference was observed between the groups in percent uterine volume reduction at each treatment week.
3 context sentences(design, population, supporting numbers)
Summary · context
A prospective randomized study.
Summary · context
Forty-one premenopausal Japanese women, 25 to 53 years of age, with uterine leiomyomata.
Summary · context
Depot type of GnRH-a, leuprolide acetate (LA) 1.88 mg or 3.75 mg was administered subcutaneously every 4 weeks for 24 weeks.
Report a problemFND-0162402505
02HumanRandomized controlled trialEfficacy outcome
In Japanese women with leiomyomata, estradiol, luteinizing hormone and follicle-stimulating hormone suppression was equal between leuprolide dose groups.
In plain wordsIn Japanese women with fibroids, hormone suppression was equal between leuprolide dose groups.
Peptide
Leuprolide
Outcome
No significant changeHormone suppression
Study
n = 41
Comparator
Leuprolide 3.75 mg every 4 weeks
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
1.88 mg every 4 weeks · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
Both groups showed significant and equal suppression of serum levels of E2, LH, and FSH.
3 context sentences(design, population, supporting numbers)
Summary · context
A prospective randomized study.
Summary · context
Forty-one premenopausal Japanese women, 25 to 53 years of age, with uterine leiomyomata.
Summary · context
Depot type of GnRH-a, leuprolide acetate (LA) 1.88 mg or 3.75 mg was administered subcutaneously every 4 weeks for 24 weeks.
Report a problemFND-0162402507
03HumanRandomized controlled trialSafety outcome
In Japanese women with leiomyomata, adverse symptom incidence did not differ significantly between leuprolide dose groups.
In plain wordsIn Japanese women with fibroids, adverse symptom incidence did not differ significantly between leuprolide doses.
Peptide
Leuprolide
Outcome
No significant changeAdverse symptoms
Study
n = 41
Comparator
Leuprolide 3.75 mg every 4 weeks
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
1.88 mg every 4 weeks · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
In addition, the incidence of adverse symptoms was not significantly different between the two groups.
3 context sentences(design, population, supporting numbers)
Summary · context
A prospective randomized study.
Summary · context
Forty-one premenopausal Japanese women, 25 to 53 years of age, with uterine leiomyomata.
Summary · context
Depot type of GnRH-a, leuprolide acetate (LA) 1.88 mg or 3.75 mg was administered subcutaneously every 4 weeks for 24 weeks.
Report a problemFND-0162402508
04HumanNon-randomized trialEfficacy outcome
In Japanese women with leiomyomata, both leuprolide dose groups showed significant suppression of estradiol, luteinizing hormone and follicle-stimulating hormone.
In plain wordsIn Japanese women with fibroids, estradiol, luteinizing hormone and follicle-stimulating hormone decreased significantly in both leuprolide dose groups.
Peptide
Leuprolide
Outcome
DecreaseEstradiol, luteinizing hormone and follicle-stimulating hormone
Study
n = 41
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
1.88 mg or 3.75 mg every 4 weeks · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
Both groups showed significant and equal suppression of serum levels of E2, LH, and FSH.
3 context sentences(design, population, supporting numbers)
Summary · context
A prospective randomized study.
Summary · context
Forty-one premenopausal Japanese women, 25 to 53 years of age, with uterine leiomyomata.
Summary · context
Depot type of GnRH-a, leuprolide acetate (LA) 1.88 mg or 3.75 mg was administered subcutaneously every 4 weeks for 24 weeks.
Report a problemFND-0162402506
05HumanNon-randomized trialEfficacy outcome
In Japanese women with leiomyomata, uterine volume decreased by 52% at week 24 with leuprolide 1.88 mg, with a 41% reduction apparent by 12 weeks.
In plain wordsIn Japanese women with fibroids, uterine volume decreased with leuprolide 1.88 mg at week 24, with a near-maximal decrease apparent by week 12.
Peptide
Leuprolide
Outcome
DecreaseUterine volume at week 24 and by week 12
Study
n: not reported in source
Outcome group
Uterine volume · Reproductive and sexual health
Studied dose
1.88 mg every 4 weeks · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Uterine volume reduction
52%
1.88 mg at week 24
Uterine volume reduction
41%
1.88 mg, near maximal, apparent by 12 weeks
Source sentences
Summary
In both groups, a significant reduction in uterine volume, 52% in 1.88 mg group and 47% in 3.75 mg group, was obtained at week 24, with near maximal reduction (41%, 45%) apparent by 12 weeks.
3 context sentences(design, population, supporting numbers)
Summary · context
A prospective randomized study.
Summary · context
Forty-one premenopausal Japanese women, 25 to 53 years of age, with uterine leiomyomata.
Summary · context
Depot type of GnRH-a, leuprolide acetate (LA) 1.88 mg or 3.75 mg was administered subcutaneously every 4 weeks for 24 weeks.
Report a problemFND-0162402501
06HumanNon-randomized trialEfficacy outcome
In Japanese women with leiomyomata, uterine volume decreased by 47% at week 24 with leuprolide 3.75 mg, with a 45% reduction apparent by 12 weeks.
In plain wordsIn Japanese women with fibroids, uterine volume decreased with leuprolide 3.75 mg at week 24, with a near-maximal decrease apparent by week 12.
Peptide
Leuprolide
Outcome
DecreaseUterine volume at week 24 and by week 12
Study
n: not reported in source
Outcome group
Uterine volume · Reproductive and sexual health
Studied dose
3.75 mg every 4 weeks · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Uterine volume reduction
47%
3.75 mg at week 24
Uterine volume reduction
45%
3.75 mg, near maximal, apparent by 12 weeks
Source sentences
Summary
In both groups, a significant reduction in uterine volume, 52% in 1.88 mg group and 47% in 3.75 mg group, was obtained at week 24, with near maximal reduction (41%, 45%) apparent by 12 weeks.
3 context sentences(design, population, supporting numbers)
Summary · context
A prospective randomized study.
Summary · context
Forty-one premenopausal Japanese women, 25 to 53 years of age, with uterine leiomyomata.
Summary · context
Depot type of GnRH-a, leuprolide acetate (LA) 1.88 mg or 3.75 mg was administered subcutaneously every 4 weeks for 24 weeks.
Report a problemFND-0162402502
07HumanNon-randomized trialEfficacy outcome
In Japanese women with leiomyomata, uterine volume decreased by 41% by week 12 with leuprolide 1.88 mg.
In plain wordsIn Japanese women with fibroids, uterine volume decreased with leuprolide 1.88 mg by week 12.
Peptide
Leuprolide
Outcome
DecreaseUterine volume at week 12
Study
n: not reported in source
Outcome group
Uterine volume · Reproductive and sexual health
Studied dose
1.88 mg every 4 weeks · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Uterine volume reduction
41%
1.88 mg by week 12
Source sentences
Summary
In both groups, a significant reduction in uterine volume, 52% in 1.88 mg group and 47% in 3.75 mg group, was obtained at week 24, with near maximal reduction (41%, 45%) apparent by 12 weeks.
3 context sentences(design, population, supporting numbers)
Summary · context
A prospective randomized study.
Summary · context
Forty-one premenopausal Japanese women, 25 to 53 years of age, with uterine leiomyomata.
Summary · context
Depot type of GnRH-a, leuprolide acetate (LA) 1.88 mg or 3.75 mg was administered subcutaneously every 4 weeks for 24 weeks.
Report a problemFND-0162402503
08HumanNon-randomized trialEfficacy outcome
In Japanese women with leiomyomata, uterine volume decreased by 45% by week 12 with leuprolide 3.75 mg.
In plain wordsIn Japanese women with fibroids, uterine volume decreased with leuprolide 3.75 mg by week 12.
Peptide
Leuprolide
Outcome
DecreaseUterine volume at week 12
Study
n: not reported in source
Outcome group
Uterine volume · Reproductive and sexual health
Studied dose
3.75 mg every 4 weeks · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Uterine volume reduction
45%
3.75 mg by week 12
Source sentences
Summary
In both groups, a significant reduction in uterine volume, 52% in 1.88 mg group and 47% in 3.75 mg group, was obtained at week 24, with near maximal reduction (41%, 45%) apparent by 12 weeks.
3 context sentences(design, population, supporting numbers)
Summary · context
A prospective randomized study.
Summary · context
Forty-one premenopausal Japanese women, 25 to 53 years of age, with uterine leiomyomata.
Summary · context
Depot type of GnRH-a, leuprolide acetate (LA) 1.88 mg or 3.75 mg was administered subcutaneously every 4 weeks for 24 weeks.
Report a problemFND-0162402504

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.